Compassionate use experience with gefitinib in poor performance (PS) patients with advanced non-small-cell lung cancer (NSCLC) treated in an expanded access program (EAP).

被引：0
|
作者：
Zinner, R
Govindan, R
Wozniak, AJ
Wade, JL
Belani, CP
Thienelt, CD
Hensing, TA
Reiling, RB
Natale, RB
Wiznitzer, I
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Washington, Sch Med, St Louis, MO USA
[3] Karmanos Canc Ctr, Detroit, MI USA
[4] Decatur Mem Hosp, Decatur, IL USA
[5] UPMC, Pittsburgh, PA USA
[6] Univ Colorado, Hlth Sci Ctr, Denver, CO USA
[7] Evanston NW Healthcare, Evanston, IL USA
[8] Presbyterian Canc Ctr, Charlotte, NC USA
[9] Cedars Sinai Comprehens Canc Ctr, Los Angeles, CA USA
[10] Lynn Reg Canc Ctr W, Boca Raton, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7082
引用
收藏
页码：636S / 636S
页数：1
相关论文
共 50 条
  • [41] LONG-LASTING DISEASE CONTROL WITH GEFITINIB IN PATIENTS (PTS) WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) LACKING THE CLASSICAL PREDICTIVE FACTORS: REPORT FROM AN EXPANDED ACCESS PROGRAM (EAP)
    Gautschi, Oliver
    Irle, Claudius
    Calderoni, Antonello
    Casty, Adrian
    Morant, Rudolf
    Baumann, Christa
    Pellicioli, Erica
    Betticher, Daniel
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1239 - S1240
  • [42] Experience from a large multi-centre expanded access programme (EAP) with gefitinib ('Iressa', ZD1839) as monotherapy in advanced non-small cell lung cancer (NSCLC)
    van Puijenbroek, R
    Bosquée, L
    Tits, G
    Germonpre, P
    Strobbe, E
    Vansteenkiste, J
    LUNG CANCER, 2005, 49 : S273 - S273
  • [43] Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
    Rogado, J.
    Pacheco-Barcia, V.
    Fenor De la Maza, M. D.
    Serra, J. M.
    Toquero, P.
    Vera, B.
    Obispo, B.
    Mondejar, R.
    Ballesteros, A.
    Donnay, O.
    Colomer, R.
    Sanchez-Torres, J. M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1915 - S1916
  • [44] Iressa in patients with advanced non-small cell lung cancer (NSCLC) progressed to chemotherapy.: Spain expanded acces program (EAP)
    Castellano, D
    Neciosup, S
    Velasco, A
    Masutti, B
    Gomez, C
    Moyano, A
    Constenla, M
    Lopez-Brea, M
    Taín, PD
    Cortes-Funes, H
    LUNG CANCER, 2005, 49 : S367 - S367
  • [45] Gefitinib in the treatment of advanced non-small-cell lung cancer
    Reck, Martin
    EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (04) : 401 - 412
  • [46] Gefitinib for refractory advanced non-small-cell lung cancer
    Moriguchi, H
    Kim, TY
    Sato, C
    LANCET, 2006, 367 (9507): : 299 - 300
  • [47] Gefitinib therapy for advanced non-small-cell lung cancer
    Liu, CY
    Seen, S
    ANNALS OF PHARMACOTHERAPY, 2003, 37 (11) : 1644 - 1653
  • [48] Gefitinib or docetaxel in advanced non-small-cell lung cancer
    Cullen, Michael
    Thatcher, Nicholas
    LANCET, 2008, 372 (9652): : 1785 - 1786
  • [49] Practical management of patients with non-small-cell lung cancer treated with gefitinib
    Shah, NT
    Kris, MG
    Pao, W
    Tyson, LB
    Pizzo, BM
    Heinemann, MH
    Ben-Porat, L
    Sachs, DL
    Heelan, RT
    Miller, VA
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (01) : 165 - 174
  • [50] Comparison of Gefitinib and Erlotinib for Patients with Advanced Non-Small-Cell Lung Cancer
    Lee, Jin Hwa
    Lee, Kyoung Eun
    Ryu, Yon Ju
    Chun, Eun Mi
    Chang, Jung Hyun
    TUBERCULOSIS AND RESPIRATORY DISEASES, 2009, 66 (04) : 280 - 287
12345